Metformin in the 6th Month of Pregnancy (Second Trimester - ~24-28 Weeks)

Why Metformin Comes Up at 6 Months

Indication and Role

• GDM diagnosed at 24-28 weeks: When glucose targets are exceeded (fasting ≥95 mg/dL, 1-hr postprandial ≥130 mg/dL, or 2-hr postprandial ≥120 mg/dL per ACOG), pharmacologic therapy is started.
• Metformin is an oral biguanide that works by reducing hepatic glucose production and improving peripheral insulin sensitivity.
• It is not FDA-approved specifically for GDM, but is increasingly used off-label alongside insulin.
• The only FDA-approved types of insulin for GDM are lispro, aspart, regular, NPH, and insulin detemir - Swanson's Family Medicine Review

Efficacy vs. Insulin

• Metformin also causes less maternal weight gain than insulin, a consistent finding across multiple systematic reviews.
• Glycemic control is comparable to insulin.

Safety Profile for Mother

• Generally well tolerated in pregnancy.
• Rare serious adverse effects include metabolic acidosis and hepatitis (as with non-pregnant use).
• Less risk of maternal hypoglycemia compared to insulin - an important safety advantage.
• Not associated with fetal malformations in either animal or human studies.
• Compatible with breastfeeding (excreted in breast milk; monitoring advised) - Rosen's Emergency Medicine

The Key Concern: Placental Transfer

• The ADA 2024 Standards of Care note that in the MiG TOFU study, 9-year-old children born to GDM mothers treated with metformin (Auckland cohort) were heavier with a higher waist-to-height ratio than those exposed to insulin. This difference was not replicated in the Adelaide cohort.
• A 2026 meta-analysis and Mendelian randomization study [PMID: 41628713] assessed congenital malformations across 11 organ systems - results are awaited for definitive conclusions on structural teratogenicity.
• Long-term data presented at ENDO 2024 showed no adverse effects on children or mothers for at least 11 years post-delivery.

Guideline Positions (2024-2026)

Practical Use at 6 Months

• Starting dose: 500 mg once or twice daily with meals, titrated up to 2500 mg/day as tolerated.
• Side effects: Nausea, diarrhea, GI upset - improved by taking with food and gradual titration.
• Supplement failure rate: 20-50% of patients on metformin alone will eventually require supplemental insulin for adequate glycemic control.
• Antenatal surveillance when GDM requires medication: twice-weekly NST or weekly BPP beginning at 32 weeks; fetal growth ultrasound every 3-4 weeks.
• Delivery timing: Well-controlled GDM on medication - by 39-40 weeks; poorly controlled - by 38-39 weeks.

Summary

Clinical note: Always individualize therapy. If a patient has pre-existing renal impairment or is at risk of lactic acidosis, metformin should be used with caution or avoided even during pregnancy.

Gestational Diabetes Insipidus (Gestational DI): Clinical Features and Management

Pathophysiology

• Vasopressinase production by the placenta begins at 7 weeks gestation
• Peaks at 22-24 weeks, correlating with placental weight (higher in multiple pregnancies)
• Results in a marked increase in metabolic clearance of vasopressin between week 10 and midpregnancy

The liver normally clears vasopressinase isoenzymes. In acute fatty liver of pregnancy or HELLP syndrome, impaired liver function causes vasopressinase to accumulate to even higher levels, dramatically worsening AVP degradation. As the liver recovers postpartum, the transient DI resolves within 4-6 weeks. - Creasy & Resnik's Maternal-Fetal Medicine

Clinical Features

• Polyuria - the cardinal feature; >2.5 L/24 hours, with urine output >250-300 mL/hour
• Polydipsia - intense thirst secondary to polyuria (intact thirst mechanism is protective)
• Nocturia - often prominent
• Symptoms typically emerge in the latter part of gestation (peak vasopressinase around 22-24 weeks) and worsen through the third trimester

• If thirst is intact and the patient drinks adequately, she may be eunatremic - appearing relatively well despite massive polyuria
• In a pregnant woman, serum sodium ≥140 mEq/L should be considered hypernatremia (given the expected physiological drop of ~5 mmol/L)
• Severe dehydration and hypernatremia can occur if DI goes unrecognized, posing risk to both mother and fetus
• Labour and parturition are usually normal in most patients with DI; fertility and lactation are generally unaffected

• May co-occur with preeclampsia, acute fatty liver of pregnancy, HELLP syndrome
• Paradoxically, if preeclampsia develops in a patient with known DI, the DI may improve temporarily (reduced placental contribution to vasopressinase)

Diagnosis

1. Confirm DI is present (hypotonic polyuria)
2. Identify likely etiology
3. Look for associated conditions

• Hyperglycemia (gestational DM - osmotic diuresis)
• Hypercalcemia, hypokalaemia
• Diuretic use
• Primary polydipsia (psychiatric origin - serum uric acid <5 mg/dL may suggest primary polydipsia)

• Central DI and gestational DI: respond to desmopressin
• Nephrogenic DI: does NOT respond to desmopressin or AVP

Management

Drug of Choice: Desmopressin (dDAVP)

• Desmopressin is a synthetic AVP analogue that acts on V2 receptors of the renal collecting duct
• It is resistant to degradation by placental vasopressinase/cysteine aminopeptidase
• It does NOT have V1a vasopressor activity (safer cardiovascular profile)
• Has been shown to be safe for mother and fetus with growing clinical experience

• Intranasal
• Oral
• Subcutaneous (if intranasal route impaired by rhinitis of pregnancy)

Management of Associated Conditions

• In HELLP / acute fatty liver: treat the underlying liver condition; DI will resolve as liver function recovers
• In pre-existing DI entering pregnancy: doses may need adjustment; 58% deteriorate, 20% improve, 15% remain unchanged during pregnancy (Hime and Richardson review, cited in Creasy & Resnik)

Postpartum

• For new-onset gestational DI: withdraw dDAVP 4-6 weeks postpartum with close monitoring of urine output and serum sodium
• If DI persists beyond 6 weeks postpartum, investigate for an underlying hypothalamic-pituitary disorder (neoplasm, lymphocytic hypophysitis, Sheehan syndrome, histiocytosis X)
• De novo DI in the first trimester, not associated with liver dysfunction and not resolving postpartum, is most likely due to unmasking of a hypothalamic-pituitary disorder and warrants full workup

Breastfeeding

• Desmopressin is compatible with breastfeeding
• Only minimal amounts pass into breast milk; monitoring of the infant is advised

Key Summary Table

Gestational Diabetes Mellitus (GDM): Clinical Features and Management

Definition

Epidemiology

• Affects approximately 5-16% of pregnancies worldwide (IDF 2021: 16% affected by GDM or pre-existing DM)
• Prevalence is rising in parallel with global obesity rates
• In the US, about 1-2% of pregnancies are complicated by diabetes overall
• GDM is the most common medical complication of pregnancy - Goldman-Cecil Medicine

Pathophysiology

1. Placental hormones - human placental lactogen (hPL), progesterone, cortisol, prolactin, and estrogen - all antagonize insulin action and cause progressive insulin resistance, peaking in the late second and third trimesters
2. In normal pregnancies, the pancreatic beta cells compensate by increasing insulin secretion (up to 2-3x baseline)
3. GDM occurs when beta-cell function is insufficient to overcome this insulin resistance
4. There is also accelerated fasting hypoglycaemia and accelerated starvation due to enhanced glucose utilisation by the feto-placental unit

Risk Factors

Clinical Features

• Increased thirst (polydipsia)
• Increased urination (polyuria)
• Fatigue
• Recurrent vaginal candidiasis
• Glycosuria on routine urinalysis

• Polyhydramnios on ultrasound (excess liquor due to fetal osmotic diuresis)
• Large-for-dates fundal height
• Fetal macrosomia on ultrasound

Complications

Maternal Complications

• Preeclampsia and pregnancy-induced hypertension
• Diabetic ketoacidosis (rare, occurs at lower blood glucose levels than in non-pregnant adults - at ~200 mg/dL rather than >300)
• Increased risk of operative delivery (caesarean section)
• Long-term: ~50% risk of developing type 2 diabetes within 10 years; 7x higher lifetime diabetes risk vs. women without GDM - Creasy & Resnik; 35-60% risk over 10-20 years - Harrison's 22E

Fetal/Neonatal Complications

Screening and Diagnosis

Who to Screen and When

Two Approaches to Screening/Diagnosis

Fasting overnight → 75 g oral glucose → measure at 0, 1, and 2 hours GDM diagnosed if any one value meets or exceeds:

• Plasma glucose at 1 hour
• If ≥130-140 mg/dL → proceed to Step 2

GDM diagnosed if ≥2 values meet or exceed (Carpenter-Coustan criteria):

One abnormal value = "gestational glucose intolerance" (not GDM) but still carries increased risk of macrosomia.

GDM Classification (ACOG)

• Class A1GDM: Controlled by diet and lifestyle alone
• Class A2GDM: Requires pharmacologic therapy

Management

Step 1: Diet and Exercise (First-Line for All)

• Carbohydrates: Limit to 35-40% of total calories; emphasise complex over refined carbohydrates
• Protein: ~20% of calories
• Fat: ~40% of calories (predominantly unsaturated)
• Meal pattern: 3 meals + 2-3 snacks daily to distribute glucose load and minimise postprandial spikes
• Total calories: individualised (generally 1800-2400 kcal/day based on pre-pregnancy BMI); weight loss and severe caloric restriction are not recommended
• Fasting or failure to gain physiological weight is not recommended

• Most pre-pregnancy exercise can be safely continued
• For sedentary women: brisk walking 20-30 minutes, 3-5 times per week
• Exercise improves insulin sensitivity and reduces postprandial glucose excursions

Step 2: Home Glucose Monitoring

• Fasting morning glucose
• 1 or 2 hours after each meal begins

Step 3: Pharmacologic Therapy (Class A2GDM)

• Rapid-acting: lispro (Humalog), aspart (NovoLog)
• Short-acting: regular insulin
• Intermediate: NPH (Humulin, Novolin)
• Long-acting: insulin detemir (Levemir)
• Note: glargine (Lantus) is not FDA-approved for GDM

• Total dose: 0.7-1.0 units/kg/day in divided doses
• Morning (2/3 of total dose): 1/3 regular + 2/3 NPH before breakfast
• Evening (1/3 of total dose): 1/2 regular + 1/2 NPH before dinner
• Titrate based on 4x/day capillary glucose (fasting + 2h after each meal)
• Insulin requirements increase with advancing gestation as placenta grows

• Metformin and glyburide are widely used off-label when insulin is not feasible/refused
• Both are not FDA-approved for GDM
• Metformin: comparable glycaemic control to insulin; less maternal weight gain; lower neonatal hypoglycaemia; crosses the placenta (long-term offspring effects under study)
• Glyburide: does NOT cross the placenta; stop ~2 weeks before delivery to prevent neonatal hypoglycaemia
• ADA 2025 still formally recommends insulin as first-line for GDM in the US; UK (NICE) and many international guidelines accept metformin as first-line after 20 weeks

Antenatal Surveillance

Postpartum Management

1. Discontinue anti-diabetic medications immediately after delivery (GDM resolves with delivery of the placenta)
2. Screen at 4-12 weeks postpartum using standard non-pregnant OGTT criteria (not HbA1c alone)
3. If normal postpartum: lifelong screening for diabetes or pre-diabetes every 3 years (ADA)
4. Lifestyle intervention and metformin both reduce progression to T2DM by 35-40% over 10 years in women with prediabetes and a history of GDM
5. Breastfeeding is encouraged (improves maternal insulin sensitivity; does not require cessation of metformin)
6. GDM is a marker of significantly increased long-term cardiovascular risk (50-85% higher CVD risk), independent of subsequent T2DM development - Creasy & Resnik

Summary Flow

24-28 weeks → Screening OGTT
       ↓
   GDM Diagnosed
       ↓
Diet + Exercise (2 weeks)
       ↓
Monitor blood glucose (fasting + 1-2h postprandial)
       ↓
Targets not met → Add Insulin (or metformin/glyburide)
       ↓
Antenatal surveillance (NST, fetal growth scans)
       ↓
Delivery at 39-40 weeks (well-controlled A2) or 40-41 weeks (A1)
       ↓
Postpartum OGTT at 4-12 weeks → 3-yearly lifelong screening

Recent evidence note: A 2024 Cochrane systematic review [PMID: 37815094] found no clear optimal intensity of glycaemic control targets for GDM - stricter control reduces macrosomia but increases small-for-gestational-age births and caesarean rates. A 2024 systematic review [PMID: 39421534] confirmed that structured exercise therapy significantly improves glycaemic outcomes in GDM.The comprehensive answer has been provided above. Here is a brief recap of what was covered:

• 1-step: 75-g OGTT - positive if any value ≥92/180/153 mg/dL (fasting/1h/2h)
• 2-step: 50-g GCT screen → 100-g 3-hour GTT if positive (≥2 abnormal values = GDM by Carpenter-Coustan: 95/180/155/140 mg/dL)

1. Diet (35-40% carbs) + exercise
2. Glucose monitoring (fasting + 1-2h postprandial)
3. Insulin if targets not met (first-line, FDA-approved); metformin/glyburide as alternatives
4. Antenatal surveillance: A1GDM = minimal; A2GDM = NST/BPP from 32 weeks, growth scans
5. Delivery by 39-40 weeks (A2) or 40-41 weeks (A1)
6. Postpartum OGTT at 4-12 weeks; 3-yearly lifelong screening